CD8 (cluster of differentiation 8)

P1/2, N=40, AbbVie | N=26 --> 40

P3, N=74, Terminated, AbbVie | Not yet recruiting --> Terminated

Furthermore, the Brucella melitensis M5-90 prpA mutant provides higher protection than the parental strain against virulent Brucella melitensis M28 infection in mice. Our findings suggest that Brucella PrpA promotes IL-10 secretion by macrophages through Tpl2 activation for bacterial survival and persistent infection, making the Brucella melitensis M5-90 prpA mutant a promising vaccine for enhanced protection.

Case 1, a 60-year-old male harboring an EGFR exon 19 deletion, received three cycles of pemetrexed, carboplatin, and pembrolizumab, followed by R0 resection; postoperative adjuvant pembrolizumab was discontinued after one cycle because of grade 2 dizziness (CTCAE v5.0). Case 2, a 52-year-old female with an EGFR exon 21 L861Q missense mutation co-occurring with TP53 and PIK3CA alterations, exhibited primary resistance to afatinib with radiographic progression after one month. She subsequently underwent three cycles of pemetrexed, carboplatin, and sintilimab, achieving R0 resection with pCR, and declined further postoperative therapy...These cases suggest that for a specific subset of EGFR-mutant NSCLC-particularly those with high PD-L1 expression and in whom targeted therapy has failed-neoadjuvant chemoimmunotherapy may serve as a potent individualized strategy capable of overcoming pre-existing immune tolerance and inducing profound pathological responses. Nevertheless, this evidence remains strictly anecdotal; validation through large-scale, prospective, biomarker-driven clinical trials is imperative before any modification of standard clinical practice.

A compact transcriptome-defined TAM-rich phenotype captures a biologically reproducible, macrophage-enriched and hypoxia-linked immune contexture in glioblastoma. It should be interpreted primarily as a quantitative immune-state classifier and tissue-correlated biological stratifier, rather than as a uniformly independent prognostic factor.

Our study uncovers extensive but heterogeneous sex-specific differences in the TME across multiple cancer types. We propose a regulatory framework linking sex chromosomes, hormone-responsive signaling and TME interactions, which is consistent with recurrent male-biased CD8⁺ T cell exhaustion and context-dependent M2-like macrophage polarization. Importantly, the magnitude and, in some cancers, the direction of these sex-biased features are modified by tissue-specific contexts. These findings underscore the need to include sex chromosome and hormone status as essential biological variables in studies of the tumor microenvironment and the design of immunotherapies.

The strong positive correlation between IDO1 and CD8+ T cells supports an adaptive immune resistance model, wherein IDO1 is induced via interferon-gamma signaling as a reactive checkpoint rather than functioning as a primary T cell exclusion factor. These findings suggest that CDKN2A-over-expressing gastric adenocarcinomas may benefit from combination immunotherapy strategies incorporating IDO1 inhibition.

Furthermore, the combination efficacy with anti-PD-1 was evaluated in a murine splenic liver-metastasis model, where SKEV@AAV reduced tumor burden, enhanced CD8+ T-cell infiltration, decreased regulatory T cells, and promoted memory T-cell differentiation. Our findings reveal a pivotal role of sKCs in mediating immune suppression in HCC-PVTT and provide a nanotherapeutic strategy that reverses sKCs' senescence, reprograms the TME, and ultimately enhances antitumor immune activation.

Functional validation in an immunocompetent mouse model showed that anti-VISTA plus cisplatin reduced tumor growth, decreased neutrophil abundance, and increased CD8⁺T-cell infiltration and granzyme B expression. CD8⁺ T-cell depletion markedly attenuated the therapeutic benefit of the combination. These findings support VISTA⁺Neus as a potential immunosuppressive neutrophil subset associated with platinum resistance and CD8⁺T-cell suppression in HGSOC, and support further investigation of VISTA-targeted strategies and the potential biomarker value of VISTA⁺Neus.

Notably, liposomal delivery of I3P facilitates efficient targeting of tumor-associated macrophages and enhances immunotherapy response without apparent toxicity. Together, these findings identify I3P as an immunoregulatory metabolite that potentiates anti-tumor immunity and support nanoparticle-mediated delivery as a promising strategy for immunotherapy sensitization in bladder cancer.

Our study comprehensively characterizes galectin family members in TNBC, revealing their prognostic significance and association with tumor microenvironment and treatment response, and highlighting the clinical and translational relevance of galectins as candidate biomarkers and hypothesis-generating molecules for future mechanistic studies.

Galectin-9/TIM-3 interaction has a possible role in the development and progression of CLL. Gal-9 mRNA expression and %TIM-3+ on CD3+, CD3+CD4+, and CD3+CD8+ T-cells are potential discriminators between CLL patients and healthy controls. This was demonstrated by high sensitivity and specificity. Additionally, they had significant correlations with prognostic markers, including β2-microglobulin, LDH, chromosomal abnormalities, CD38, and Rai stage.